16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends

Author:

Cohen Hannah12ORCID,Cuadrado Maria J3,Erkan Doruk4,Duarte-Garcia Ali56ORCID,Isenberg David A27ORCID,Knight Jason S8,Ortel Thomas L9,Rahman Anisur7,Salmon Jane E10,Tektonidou Maria G11ORCID,Williams David J212,Willis Rohan13,Woller Scott C14ORCID,Andrade Danieli15

Affiliation:

1. Haemostasis Research Unit, Department of Haematology, University College London, London, UK

2. University College London Hospitals NHS Foundation Trust, London, UK

3. Rheumatology Department, Clinica Universidad de Navarra, Madrid, Spain

4. Barbara Volcker Center for Women and Rheumatic Disease, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, USA

5. Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA

6. Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota, USA

7. Centre for Rheumatology, Division of Medicine, University College London, London, UK

8. Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA

9. Division of Hematology, Department of Medicine, and Department of Pathology, Duke University Medical Center, Durham, NC, USA

10. Division of Rheumatology, Hospital for Special surgery, Weill Cornell Medicine, New York, NY, USA

11. First Department of Propaedeutic Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece

12. UCL EGA Institute for Women’s Health, University College London, London, UK

13. Antiphospholipid Standardization Laboratory, University of Texas Medical Branch, Galveston, TX, USA

14. Department of Medicine, Intermountain Medical Center, Murray UT; Division of General Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA

15. University of São Paulo, São Paulo, Brazil

Abstract

Antiphospholipid syndrome (APS), an acquired autoimmune thrombophilia, is characterised by thrombosis and/or pregnancy morbidity in association with persistent antiphospholipid antibodies. The 16th International Congress on Antiphospholipid Antibodies Task Force on APS Treatment Trends reviewed the current status with regard to existing and novel treatment trends for APS, which is the focus of this Task Force report. The report addresses current treatments and developments since the last report, on the use of direct oral anticoagulants in patients with APS, antiplatelet agents, adjunctive therapies (hydroxychloroquine, statins and vitamin D), targeted treatment including rituximab, belimumab, and anti-TNF agents, complement inhibition and drugs based on peptides of beta-2-glycoprotein I. In addition, the report summarises potential new players, including coenzyme Q10, adenosine receptor agonists and adenosine potentiation. In each case, the report provides recommendations for clinicians, based on the current state of the art, and suggests a clinical research agenda. The initiation and development of appropriate clinical studies requires a focus on devising suitable outcome measures, including a disease activity index, an optimal damage index, and a specific quality of life index.

Publisher

SAGE Publications

Subject

Rheumatology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3